Lumipulse® G CA125-II
Immunoreaction cartridges for in vitro diagnostic (IVD) use with the LUMIPULSE G System for the quantitative measurement of CA125 in serum or plasma.
The assay utilises proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in up to 35 minutes.
Product number 292631
-
Documentation
Browse regulatory documents for this product
Create a (free!) eServices account and start browsing all regulatory documentation right away.
Get access to this section and more
Create a free eServices account now and instantly access multiple digital resources:
- Regulatory product documentation
- Selected scientific posters
- Product leaflets
- How-to videos and more…
-
Insights
Therapeutic strategies for ovarian cancer and the use of biomarkers for monitoring prognosis
Over the last decades, biomarkers have become an extremely important tool in the care of patients with ovarian cancer. Biomarkers are capable of...
Mar 1, 2021
An overview of ovarian cancer: the development of biomarkers for early detection
It has been estimated that in 2020, about 21,750 women in the US will receive a new ovarian cancer diagnosis and about 13,940 women will die from this...
Jul 29, 2020
Did you know? The discovery of the CA125 biomarker
CA125, also known as mucin 16 or MUC16 is a member of the mucin family glycoproteins. Based on early experience with immune therapy for cancer...
Dec 28, 2018
-
FAQ
How does the coronavirus disease Covid-19 impact Fujirebio's operations?
Please see the following statement on the impact of coronavirus disease Covid-19 on the operations of Fujirebio Europe (updated January 19, 2021).
-
Related products
-
Product inquiry
